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Introduction 
The development of a transdermal delivery device for a drug can be a rather 
complicated and time-consuming task. The drug itself must obviously first show 
physicochemical properties propitious for topical delivery, eg low daily dosage and 
good skin permeability. The Galenical problem is then primarily that of developing 
a device that on application to the skin in vivo yields a satisfactory drug plasma 
profile. The important properties of the device in this respect are the rate, extent and 
duration of drug release. For the case of a matrix-type device, these can be adjusted 
in some measure by modifying matrix thickness, drug loading and drug diffusivity 
within the matrix. The drug release rate from a membrane-controlled device 
depends on drug loading of the reservoir, thickness of the rate-controlling 
membrane, drug diffusivity within the rate-controlling membrane, and the size of 
any loading dose present. The drug release properties of either type of device can 
readily be determined by in vitro experiment. An in vivo study can be undertaken to 
determine the drug plasma and urinary excretion profiles obtained from the device. 
At this stage, the formulator may well be interested in predicting how alterations in 
the Galenical properties of the device or changes in the permeability of the skin 
would influence these in vivo profiles. For the successful prediction of these effects, 
a model is required that describes — with suitable exactitude — the 
physicochemical and biological processes involved. Much advance has been made 
in this field of pharmaceutical research during the last ten years. Both 
compartmental1 and combined diffusion/compartmental2,3 models of varying 
complexity have been proposed. In this paper we relate how basic models for the 
prediction and evaluation of transdermal drug delivery have been developed using a 
simple numerical technique. 
Model description and evaluation 
As recognized some years ago,4 the morphological problem of transdermal drug 
delivery can be represented by a multilayer model of the type illustrated in Figure 1. 
The outermost, left-hand layer (B) represents the delivery device, which is attached 
in some way to the outer surface of the skin (C). The drug present within the device 
is released at a rate dependent on the device's structure and properties. The 
physicochemical processes of first importance here are passive diffusion of the drug 
and its partitioning at any boundaries where the properties of the medium change, 
eg at x=C, between the device and the outermost skin layer. The kinetics of 
partitioning may also need to be considered.5 The stratum corneum, together with 
any surface lipid, is represented by the second layer of the model (D). Although this 
tissue has an intricate internal structure, the simplification that it behaves as an 
isotropic layer has been successfully applied to numerous quantitative studies of 
drug transport through skin. Passive diffusion is again the important process within 
this layer, although others, such as sorption of the drug, may also occur. The viable 
epidermis is represented by the next layer of the model (F), as it is known to form a 
morphologically distinct layer within the skin. 6 Partitioning must be considered at 
the plane E, together with passive diffusion within the viable epidermis itself. The 
treatment of this layer as a compartment can be justified, however, since its 
resistance to the diffusional movement of drug molecules is many times less than 
that of the adjacent stratum corneum. Thus, although the drug arrives slowly at the 
outermost side of the viable epidermis (E), it then diffuses very rapidly through this 
layer as a consequence of its high permeability. The drug concentration within the 
viable epidermis can, therefore, be considered as being the same everywhere, ie as 
being only a function of time. The next morphological layer of the skin is the 
dermis. Because this tissue contains an extensive network of capillaries extending 
up to the junction with the viable epidermis, it can be combined with the blood as a 
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Figure 1 Multilayer representation of transdermal drug delivery. 
single compartment (H). Once present within the blood, the drug may be distributed 
into the peripheral tissues and will be eliminated. 
Each layer of this scheme has characteristic drug transport properties which 
differ substantially from those of the neighbouring layers. It is therefore possible to 
characterize drug transport within an individual layer by examination of the 
physicochemical processes occurring there. For example, it is relatively easy to 
measure drug transport within either of the two outer layers of the model, namely, 
the delivery device and the stratum corneum. Once knowledge of the drug transport 
properties of the individual layers is available, a basic model can be assembled to 
describe the complete process of transdermal drug delivery, as represented by the 
scheme in Figure 1. We start by considering measurement of drug transport within 
excised human stratum corneum and a matrix-type delivery device. 
Model I: stratum corneum 
Isolated sheets of human stratum corneum can be readily prepared from whole skin 
excised from cadavers.7 The transport properties of a drug within this tissue can be 
characterized by measuring its permeation from a donor medium through the tissue 
and into an acceptor medium. A diffusion cell of some standard design8 can be 
used. For the model discussed here, the stratum corneum will exist in the hydrated 
state. The standard representation of this diffusional problem is given in Figure 2 for 
an assumed isotropic sheet of stratum corneum of thickness h. The drug 
concentration within the stratum corneum, c s c(x,t), is given as a function of space, x, 
and time, t, by Fick's second law. Provided the ratio of radius to thickness of the 
sheet (r/h) is > ca 100, linear diffusion can be assumed: 
where D s c is the drug diffusivity within the stratum corneum (cm 2sec _ 1). The 
subscripts x and t denote the respective partial derivatives. Initially, the drug is 
contained within the donor medium: 
The non-sink transport of drug at the two boundaries is given by Fick's first law: 
D s c c s c ( x , t ) x x - c s c ( x , t ) t = 0, 0<x<h, t>0, (1) 
c d(0) = c o , c a(0) = 0, (2) 
c s c(x,0) = 0, 0<x<h. (3) 
ma'(t) = Dsc.CscCO^x, t>0, (4) 
m a'(t) = D s c .c s c (h,t) x , t>0, (5) 
where m(t) denotes drug mass and a' a first ordinary derivative. The drug 
concentration in the acceptor is given by: 
ca(t) = c s c(h,t)/K, t>0, (6) 
where K is the drug's partition coefficient between stratum corneum and acceptor 
medium. The analytical solution to this problem 9 is an awkward transcendental 
function, not particularly convenient for the evaluation of experimental data. A 
more flexible way of treating it is to employ the numerical analysis developed by 
Crank and Nicolson especially for solving partial differential equations of the 
diffusion type. 1 0 Equations 1-6 are expressed in finite differences to yield algebraic 
approximations in the form of a tridiagonal matrix. The solution can be obtained by 
Gauss' elimination method and programmed in Pascal on a personal computer. It is 
advisable to have the capacity of at least an 80 386 processor with 80 387 
co-processor. 
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Figure 2 Diffusional model for drug permeation through an excised stratum 
corneum membrane. 
The programme can be used to simulate drug permeation through an isolated 
sheet of stratum corneum, showing how the parameters diffusivity, membrane 
thickness and partition coefficient influence the drug concentration profile within 
the stratum corneum, c s c(x,t), and the profile of drug mass in the acceptor, ma(t).11 
Additionally, it is possible to calculate the diffusivity and partition coefficient from 
experimental data. Figure 3 shows an example of some experimentally determined 
co-ordinates of ma(t), obtained for the permeation of the basic drug clenbuterol 
(MW=277, pka=9.5) through excised human stratum corneum. The typical 
permeation profile is seen. The curve passing through these co-ordinates is the 
numerical solution to Equations 1-6 which best fits the data, as determined by 
Nelder and Mead's improved simplex method. 1 2 Although not obvious to the eye, 
the fitted curve is sigmoidal in shape, as a result of the prevailing non-sink boundary 
conditions. The point of inflexion occurs after ca 60 hours, which corresponds to a 
value of 0.023 for m ^ / m o . Thus, the point of maximum flux is reached when only 
2.3% of the drug has arrived in the acceptor. Detailed investigations showed that the 
accuracy of the ma(t) values in this case was such that a weighting factor need not 
be used at the short times. The curve fit gives a diffusivity of 3.97xl0~ 1 2 ± 
2.33x10~ 1 2cm 2sec _ 1 and a partition coefficient of 212 ± 165(n=6). 
The large standard deviations can be taken to arise from two sources: firstly, 
natural variation in the anisotropic nature of the stratum corneum, and, secondly, 
error in the determination of the thickness of the stratum corneum. Much less scatter 
is found with permeation measurements made on an isotropic silicone membrane of 
known thickness, for example, with coefficients of variation of 5% for diffusivity 
and 12% for partition coefficient. These variations can be fully accounted for by 
experimental error in the determination of c 0 and ma(t). Equation 1 is, strictly 
speaking, not applicable to stratum corneum. The simplest attempts to overcome the 
problem of anisotropy involve retaining Equation 1, and making purely algebraic 
calculations based on the geometry of a 4bricks-and-mortar' representation of the 
microstructure of the stratum corneum. 1 3 ' 1 4 The derivation of a comprehensive 
diffusional model for the stratum corneum based on solutions to Fick's second law 
represents a formidable, yet challenging, mathematical task. Although a model of 
such intricacy would be intellectually more satisfying, it remains to be seen if it 
would offer any practical advantage over the simple assumption of isotropy within 
the stratum corneum. 
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Figure 3 Fit of experimental co-ordinates of ma(t) for clenbuterol permeation 
through excised human stratum corneum to numerical model (curve). 
Model II: polymer matrix 
The transport properties of a drug within a polymeric matrix of thickness L , 
intended for use as a transdermal delivery device, can be conveniently obtained 
from measurement of the rate of drug release into an adjacent acceptor medium. For 
a thin matrix (r/h>ca 100), the standard representation shown in Figure 4 can again 
be characterized by the linear form of Fick's second law: 
D m . c m ( x , t ) x x - cm(x,t) t = 0, -L<x<0, t>0, (7) 
where cm(x,t) is the drug concentration within the matrix and D m its diffusivity. The 
drug is initially homogeneously dissolved within the matrix: 
cm(x,0) = c 0 , -L<x<0, (8) 
c a(0) = 0. (9) 
The outer, left-hand side of the matrix is insulated, and the drug is released at x=0 
into a non-sink: 
c m ( -L , t ) x = 0, t>0 (10) 
ma(t)' =-D m . c m (0 , t ) x , t>0. (11) 
The drug concentration in the acceptor is governed by: 
c a (0 = cm(0,t)/K', (12) 
where K ' is the drug's partition coefficient between matrix and acceptor medium. 
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Figure 4 Diffusional model for drug release from a rectangular polymer matrix. 
Numerical analysis of this problem is again more flexible than use of the 
analytical solution, 1 5 and yields simulated release profiles of ma(t) as a function of 
diffusivity, matrix thickness and partition coefficient.1 1 Figure 5 shows an example 
of experimentally determined co-ordinates of ma(t) for the release of clenbuterol 
from a thin (50^m) matrix prepared from a purified form of Eudragit NE30D 
(Rohm Pharma). Again, the curve is the numerical solution to Equations 7-12 
which best fits the data. The fitted diffusivity of 9.31 x l ( H 2 ± 0 . 7 x l O - ^ c m ^ e c " 1 
(n=4), for a drug loading of 8% w/w, has a coefficient of variation of ca 7%, which 
can be accounted for solely by experimental error in the determination of c 0 and 
ma(t). The former is most accurately determined from the weight ratio of drug to 
polymer used for the preparation of the matrix by (in this case) solvent evaporation. 
Difficulties arise with the fitting of the best value for a partition coefficient. The 
values obtained show enormous variation, some being quite unrealistically large. 
The matrix comprising the finite-difference forms of Equations 7-12 is undoubtedly 
non-singular, implying the existence of unique values for both D and K ' . The failure 
to fit K ' is caused by its extremely small influence on the release profiles generated 
with the model. Thus, immediately t becomes greater than zero, the drug 
concentration within the outermost layer of the matrix falls sharply in accordance 
with the assumption of spontaneous partitioning at x=0 implicit in Equations 11 and 
12. This results in very small values for ca(t) in the case of matrix/acceptor partition 
coefficients > 1. Because ca(t) is so small, K ' exerts negligible influence on the 
concentration gradient in Equation 11, and hence the release rate. This insensitivity 
to K ' makes the D/K'-simplex plane very flat in the K'-direction. For values of K ' in 
excess of ca 100, the curve-fit cannot converge sharply on K ' , despite converging 
well on D. The measured matrix/buffer partition coefficient for clenbuterol is 120. 
This is, indeed, a known problem with the Nelder-Mead method. 1 2 
400 
Figure 5 Fit of experimental co-ordinates of ma(t) for clenbuterol release from a 
purified Eudragit NE30D matrix to numerical model (curve). 
Model III: transdermal delivery from a matrix-type device 
This model directly links the transport properties of the device and the stratum 
corneum (ie Models I and II above) to the drug plasma and urinary excretion 
profiles obtained during topical application of the device. It can be viewed as a 
somewhat refined version of a combined diffusion/compartmental model presented 
by Tojo. 2 It has the advantage over previous models in that it is not necessary to 
specify particular drug release kinetics from the device or to assume the existence of 
steady-state or sink conditions. The two-dimensional representation is shown in 
Figure 6. The release of drug from the matrix of thickness L , and its subsequent 
permeation through the stratum corneum of thickness h, are governed by the linear 
form of Fick's second law. For the matrix, this involves the use of Equations 7, 8 
and 10; for the stratum corneum, Equations 1 and 3 are required. These two layers 
are in perfect diffusional contact at x=0: 
D m .c m (0 , t ) t = D s c .c s c (0,t) t , t>0. (13) 
Owing to the very low diffusional resistances existing within the underlying 
tissues, each is represented by a compartment. This results in a three-compartment 
model with five first-order rate constants, joined at x=h to the double diffusion layer: 
b.Ce'(t) = -Dsc.Cscth,^, (14) 
where ce(t) is the drug concentration in the viable epidermis/dermis compartment of 
'thickness' b. The drug mass in the plasma, mp(t), is then given by: 
mp'(t) = k 1 2 .m e(t) - {k2i+ke+k23}.mp(tHk23.mt(t), (15) 
and the eliminated mass, mu(t), by: 
mu'(t) = ke.mp(t). (16) 
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Figure 6 Model for transdermal drug delivery from a matrix-type device. 
The numerical solution programmed in Pascal can be used to evaluate in vivo 
data and obtain values for those system constants that cannot be determined from 
independent experiments, ie k j 2 and k2i . It can also be used to simulate the effects 
of the system parameters on the drug plasma profile, eg drug diffusivity within 
matrix and stratum corneum, and drug loading and thickness of the matrix.3 A 
simulation for clenbuterol using the values obtained for D m and D s c from the first 
two models yields, however, the rather unsatisfactory drug plasma profile shown in 
Figure 7 (lower curve). It does not reach a maximum after an application time of 
seven days; this finding does, however, agree with in vivo data obtained during the 
transdermal application of this drug from a polymer matrix.3 This is certainly due to 
the drug's long half-life. A simulated 5-fold increase in D s c — as could feasibly be 
achieved for this drug with Azone R — does not greatly improve the profile (upper 
curve in Figure 7). Indeed, only an extension of the simulation time to 28 days 
(insert to Figure 7) shows how a maximum in the plasma profile is first reached at a 
t m a x of call days. 
Figure 7 Simulated drug plasma profiles for transdermal drug delivery from a 
matrix-type device (D m =9.3xl0~ 1 2 cm 2 sec _ 1 ; D s c =4xl0~ 1 2 cm 2 sec - 1 (lower curve), 
D s c = 2 x l 0 - n c m 2 sec - 1 (upper curve); c 0 = 1.25mg/2cm2; K = l ; K ' = l ; L=68(im; 
h=15|im; b=50^im; k 1 2=2h" 1; k 2i=12h- 1; k23=0.2h"1; k 3 2=0.51r 1; ^=0.028^*; 
A=2cm 2; V(j=901). Insert: extended simulation up to 28 days for D s c =4xl0~ 1 2 
(lower curve) and 2 X 1 0 - 1 1 (upper curve) cm 2 sec - 1 . 
Model IV: transdermal delivery from a membrane-controlled device 
It may be possible to reduce the predicted t m a x of 21 days for transdermal 
clenbuterol by incorporating a 'loading dose' of drug into the system. This can best 
be illustrated for the case of a membrane-controlled transdermal device, 
necessitating a slight modification to Model III. Thus, the two outer layers of the 
scheme shown in Figure 8 now represent the device, comprising a drug reservoir, in 
which the drug concentration is only time-dependent, enclosed by a rate-controlling 
membrane of thickness a. The membrane will contain an initial loading dose of drug 
(ie cm e(x,0)>0) as a result of the partitioning equilibrium at x = -a (partition 
coefficient = K i ) . Non-sink transport of the drug occurs at this boundary: 
m r(t)' = D m e . c m e ( - a , t ) x , t>0, (17) 
where mr(t) is drug mass within the reservoir and cm e(x,t) is the drug concentration 
within the membrane. Upon application of the device to the skin (at t=0), the drug 
partitions at x=0 from the membrane into the stratum corneum (partition coefficient 
= K2) and diffuses up to the boundary with the viable epidermis/dermis 
compartment. Within the rate-controlling membrane: 
Dme.CmeOc,t)x x - C m e (x , t ) t = 0, -a<X<0, t>0, (18) 
where D m e is the drug diffusivity. The boundary condition at x=0, between 
rate-controlling membrane and stratum corneum, describes perfect diffusional 
contact: 
D m e . c m e (0 , t ) t = D s c .c s c (0,t) t , t>0. (19) 
Equation 1 is valid for the stratum corneum. The boundary condition at x=h, 
between stratum corneum and the viable epidermis/dermis compartment, is the 
same as Equation 14. The three-compartmental part is identical to that for Model III, 
with the drug plasma and urinary excretion profiles again being given by Equations 
15 and 16, respectively. 
The numerical solution to the complete model enables calculations to be made 
for a device having a rate-controlling membrane made of the same polymer as the 
matrix, namely, Eudragit NE30D. The drug plasma profiles shown in Figure 9 were 
thus all simulated for a membrane diffusivity of l x l O - 1 1 c m 2 s e c _ 1 , a membrane 
thickness of 10|xm, and a membrane/lipoid-reservoir partition coefficient, K\, of 
0.1. The lowest curve represents an initial drug concentration in the reservoir, c r(0), 
of lOmgcm - 3 (all dissolved; no suspended drug present), which produces, by virtue 
of equilibrium partitioning at x = -a , an initial drug loading in the membrane, 
cm e(x=0), of l m g c m - 3 , ie c r(0)/cm e(x,0)=0.1. This plasma profile is, however, no 
better than those profiles seen for the matrix system in Figure 7. Yet, by holding 
c r(0) and K j constant, and artificially increasing c m e (x,0) to lOmgcm" 3 (top curve in 
Figure 9), a much more promising drug plasma profile is obtained. The t m a x is 
x=-a x=0 x=h x=h*b 
J . 
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Figure 8 Model for transdermal drug delivery from a membrane-controlled device. 
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Figure 9 Simulated drug plasma profiles for transdermal drug delivery from a 
membrane-controlled device (cr(0)=10mgcm"3; Ki=0.1; D m e =9 .3x lO" 1 2 cm 2 sec - 1 ; 
cm e(x,0)=lmgcm~ 3 (lower curve), cm e(x,0)= 1 Omgcm - 3 (upper curve); all 
compartmental constants as given in Figure 7). 
Cplt) 
125 
lpg/ml] 
-
I • T _ T • " T 
^ ^20pm 
^ 15 pm -
^ _10pm ^ ^ ^ - ^ 
I / = 
1/ — ^ a 
1 1 
-
0 1 2 3 4 5 6 
tld] 
Figure 10 Effect of membrane thickness on simulated drug plasma profiles for 
transdermal drug delivery from a membrane-controlled device (cme(x,0)=10mgcm~3; 
all other constants as given in Figure 9). 
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Figure 11 Effect of diffusivity within membrane on simulated drug plasma profiles 
for transdermal drug delivery from a membrane-controlled device 
(cm e(x,0)= lOmgcm - 3 ; a=10(im; all other constants as given in Figure 9). 
reduced to ca 2.5 days, a value comparable with that found for the transdermal 
application of a clonidine T T S . 1 6 Additionally, c m a x lies within the correct 
therapeutic range for clenbuterol, of ca lOOpgml - 1. It must be remembered, 
however, that this loading dose of 1 Omgcm - 3 is in excess of that arising purely from 
equilibrium partitioning between reservoir and membrane (ie only lmgcm - 3 ) . A 
special design would, therefore, be required for the device, to prevent the excess 
loading dose partitioning backwards into the reservoir upon storage. An interesting 
effect can be observed by altering membrane thickness whilst retaining a c m e(x,0) of 
1 Omgcm - 3; by halving the membrane thickness from its original 10|Lim to 5 | im 
(Figure 10), the drug plasma profile becomes much flatter and t m a x increases 
greatly. Although c m e (x,0) is the same for all membrane thicknesses, a thinner 
membrane contains less drug mass, thereby effectively reducing the loading dose 
and nullifying its beneficial effects on the drug plasma profile. An increase in 
thickness above 10|im raises the drug plasma profile, but also increases t m a x . In 
these cases, it takes a longer time to reach the higher c m a x , since all diffusivities and 
partition coefficients within the system remain the same. Increasing the diffusivity 
within the rate-controlling membrane from l x l O " 1 1 to lx lO" 1 0 cm 2 sec" 1 , whilst 
keeping a c m e (x,0) of 1 Omgcm - 3 and a thickness of 10(im, decreases the drug 
plasma profile over the first six days (Figure 11). This effect is also related to a 
detrimental influence on the loading dose. Thus, by increasing D m e , not only is the 
forward diffusion at x=0 into the stratum corneum accelerated, but also the 
backward diffusion of the loading dose at x = - a into the drug reservoir. The 
beneficial influence of the loading dose is thereby nullified once more. 
Conclusion 
The two models discussed here for transdermal drug delivery are clearly not 
comprehensive; various processes are not considered which may be of 
importance for the drug plasma profile, eg drug metabolism within the viable 
tissues, the presence of a resistive adhesive layer between matrix or membrane 
and the stratum corneum, or possible drug distribution into erythrocytes. It is a 
relatively straightforward matter to incorporate such processes into the 
numerical model, allowing further simulations to be made. It must, however, be 
recognized that the growing complexity of the models leads to an increase in the 
error associated with their use to evaluate experimental data. This is especially 
the case with in vivo data, where the experimental scatter is likely to be rather 
large. 
Recognition of the anisotropic structure of the stratum corneum could lead 
to an interesting further development of Model I. In vitro experiments with skin 
lipids indicate that drug diffusivities within the lipid fraction of the stratum 
corneum are probably ca 10 - 8 cm 2 sec - 1 . Yet drug diffusivities calculated from 
permeation data through excised human stratum corneum are some 103— 10 4 
times smaller with the assumption of isotropicity. Calculations based on a 
simple bricks-and-mortar structure yield, however, multiplication factors of just 
this order, indicating that the outstanding barrier properties of the stratum 
corneum may be largely of geometrical origin. The critical factors are probably 
the extended diffusional pathway across the thickness of the stratum corneum, and 
the very small effective diffusional area within the stratum corneum. It may also be 
of interest to examine the influence of non-spontaneous partitioning5 for Models I 
and II. 
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